Knockdown of BSP or the use of BSP inhibitors may be a more feasible and effective approach for cancer therapy than integrin-targeted therapeutics due to several reasons, that is, integrins sharing the same subunits and the complexity of the integrin signalling cascade. The gene discussed is IBSP; the disease is cancer.